IMMX
Immix Biopharma, Inc.·Healthcare
9.26
5.026%(−0.49)
Market ClosedLast Updated: — ET
52W L: $1.5652W H: $11.61
IMMX NEWS
globenewswire.com
1d ago
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
defenseworld.net
5d ago
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $18.25
Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation
globenewswire.com
Mar 30
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Johnson & Johnson for BLA submission –
defenseworld.net
Mar 16
Immix Biopharma (IMMX) to Release Earnings on Monday
Immix Biopharma (NASDAQ: IMMX - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Immix Biopharma to post earnings of ($0.16) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the
globenewswire.com
Mar 3
Immix Biopharma to Participate in Upcoming Investor Conferences
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences:
globenewswire.com
Jan 28
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting –
